Table1 The clinical experiment of therapies for IBD
From: Colitis-associated carcinogenesis: crosstalk between tumors, immune cells and gut microbiota
Drug | Target | Disease | Phase | No. of patients | Interventions | Study Completion Date |
|---|---|---|---|---|---|---|
PF-04236921 | IL-6 | Crohn’s disease | Phase II | 250 | Drug: PF-04236921 SC injection | February 2015 |
Esketamine | IL-6 | Crohn’s disease | Phase IV | 120 | Drug: Esketamine; Drug: Placebo | March 2022 |
UTTR1147A | IL-22 | Ulcerative colitis; Crohn’s disease | Phase II | 143 | Drug: UTTR1147A | July 2022 |
ABX464 | IL-22 | Ulcerative colitis | Phase II | 32 | Drug: ABX464; Drug: Placebo oral capsule | September 2018 |
Mirikizumab | IL-23 | Crohn’s disease | Phase II | 191 | Drug: Mirikizumab; Drug: Placebo | February 2021 |
Risankizumab | IL-23 | Crohn’s disease | Phase II | 121 | Drug: Risankizumab IV; Drug: Risankizumab SC; Drug: Placebo | November 2016 |
Ustekinumab | IL-23, IL-12 | Crohn’s disease | Phase II | 526 | Drug: Placebo; Drug: Ustekinumab | December 2010 |
Adalimumab | TNF-α | Moderate to severe Crohn’s disease | Phase IV | 100 | Drug: Adalimumab | January 2017 |
Golimumab | TNF-α | Ulcerative colitis | Phase IV | 112 | Drug: Golimumab | September 2019 |
Certolizumab | TNF-α | Crohn’s disease | Phase IV | 20 | Drug: Certolizumab Pegol | October 2018 |
Infliximab | TNF-α | Ulcerative colitis | Phase IV | 21 | Drug: Infliximab | November 2012 |
SHR0302 | JAK1 | Crohn’s disease | Phase II | 144 | Drug: SHR0302; Drug: Placebos | December 2021 |
Upadacitinib | JAK1 | Crohn’s disease | Phase III | 524 | Drug: Upadacitinib; Drug: Placebo for Upadacitinib | January 2022 |
ABT-494 | JAK1 | Crohn’s disease | Phase II | 220 | Drug: Placebo; Drug: ABT-494 | August 2017 |
PF-06651600 | JAK3 | Ulcerative colitis | Phase II | 319 | Drug: PF-06651600 or Placebo; Drug: PF-06700841 or Placebo; Drug: PF-06700841; Drug: PF-06651600 | May 2021 |
PF-00547659 | MAdCAM-1 | Crohn’s disease | Phase II | 268 | Drug: PF-00547659 | July 2016 |
MT-1303 | S1P1 | Crohn’s disease | Phase II | 46 | Drug: MT-1303 | August 2017 |
Vedolizumab | α4β7 | Inflammatory bowel disease | – | 24 | Drug: Vedolizumab | February 2019 |
Abrilumab | α4β7 | Ulcerative colitis | Phase II | 359 | Biological: Abrilumab; Drug: Placebo | April 2018 |